TCP-1, a novel peptide to diagnose early colon cancer
Hang Yu(Humboldt-Universität zu Berlin), Yan Wang(National Institute of Biological Sciences, Beijing), Chong‐Jing Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Min Huang(East China University of Technology), Hao Lin(Chinese Academy of Medical Sciences & Peking Union Medical College), Sen Zhang(Shanxi Medical University), Li‐Bin Pan(Zhejiang Cancer Hospital), Yan Li(Chinese University of Hong Kong), Cong Lin(Jinan University), Bao‐Ying Wen(Chinese Academy of Medical Sciences & Peking Union Medical College), Chi‐Hin Cho(Chinese University of Hong Kong), Ru Feng(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoguang Chen(Macau University of Science and Technology), Manyi Xu(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 2
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson’s disease by regulating gut microbiota
|Signal Transduction and Targeted Therapy|2021|315
Abnormal metabolism of gut microbiota reveals the possible molecular mechanism of nephropathy induced by hyperuricemia
|Acta Pharmaceutica Sinica B|2019|217
Berberine treats atherosclerosis via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway in gut microbiota
|Signal Transduction and Targeted Therapy|2022|186